ERBB2 and breast cancer: While BC organoids can closely retain the characteristics of PBCs in hormone receptor (HR)-positive and HER2-positive BC, they differ significantly from PBCs in stemness, hypoxia-related pathways, and drug sensitivity in TNBC [232].